Acetylcholine, a neuronal signaling molecule, is found to be depleted in AD brain and has been linked to decline in cognitive function observed in AD sufferers; hence acetylcholinesterase inhibitors (AChEI) have become important in the regulation of AChE and prolonging the acetylcholine levels at the synaptic clefts. Here, ACHE is linked to Alzheimer disease.